Precigen's Q3 2025 results showed rising revenues from its newly approved PAPZIMEOS therapy, but the quarter was marked by a significant net loss due to a large non-cash adjustment in warrant liabilities and increased commercialization expenses.

Precigen reported a net loss of $54.2 million for the first quarter of 2025, compared to a net loss of $23.7 million in the same period last year. Total revenues increased to $1.341 million, up from $1.065 million in Q1 2024, primarily due to increased product and service volumes. The company's cash, cash equivalents, and investments totaled $81.0 million as of March 31, 2025, anticipated to fund operations into 2026.

In Q4 2024, Precigen reported $1.19 million in revenue and a net loss of $19.73 million, with an EPS of -$0.06. The company continued preparations for the anticipated commercial launch of PRGN-2012 in 2025 and successfully extended its cash runway into 2026.

Precigen reported a net loss of $24.0 million, or $(0.09) per basic and diluted share, for the third quarter of 2024. The company is focused on advancing PRGN-2012 and preparing for its potential launch in 2025, while also exploring strategic partnerships.

Precigen reported a decrease in total revenues and an increase in net loss for the second quarter of 2024 compared to the prior year period. The company strategically reprioritized its pipeline to focus on PRGN-2012 and strengthened its cash position through a public offering.

Precigen reported its Q1 2024 financial results, noting a decrease in total revenues and an increase in research and development expenses. The company is preparing for a potential commercial launch of PRGN-2012 in 2025 and is evaluating financing opportunities to strengthen its balance sheet.

Precigen reported its full year 2023 financial results, with key highlights including progress in its AdenoVerse and UltraCAR-T programs. The company anticipates a transformative year in 2024, with pivotal Phase 2 data expected in Q2 and a BLA submission for PRGN-2012 in the second half of the year. A $10.4 million impairment charge was recorded in Q4 related to Exemplar subsidiary.

Precigen reported a decrease in total revenues by 92% compared to Q3 2022, alongside reductions in research and development and SG&A expenses. The company is focusing on advancing its lead asset, PRGN-2012, and managing its balance sheet through cost-saving measures and exploring non-dilutive capital opportunities.

Precigen reported its Q2 2023 financial results, highlighting a loss from continuing operations of $20.3 million, or $(0.08) per basic and diluted share. The company is prioritizing its portfolio activities to maximize the potential success of PRGN-2012 and has extended its projected cash runway into 2025 through cost-saving measures and a capital raise.

Precigen reported its Q1 2023 financial results, highlighting the successful closing of a public offering, regaining rights to CD19 and BCMA targets, and advancements in UltraCAR-T portfolio. The company is focused on strengthening its financial footing while advancing promising programs.

Precigen's Q4 2022 saw a decrease in total revenues by $1.9 million compared to the prior year period, alongside a reduction in research and development expenses. The company's loss from continuing operations was $22.2 million, an improvement from the previous year's $26.7 million.

Precigen reported increased total revenues driven by collaboration and licensing agreements, offset by a decrease in product and service revenues. The company's loss from continuing operations improved compared to the prior year. Precigen also retired $144.0 million of convertible notes, strengthening its financial position.

Precigen is focusing on maximizing the value of their highest priority assets and prioritizing capital allocation to reach critical inflection points in clinical trials. The sale of Trans Ova Genetics is expected to close in Q3 2022, providing $170 million in cash up-front and up to a $10 million earn-out over the next two years.

Precigen reported a 31% increase in total revenues compared to the quarter ended March 31, 2021, driven by higher product and service revenues from Trans Ova and Exemplar. The company's loss from continuing operations improved to $19.3 million, or $(0.10) per basic share, compared to $21.8 million, or $(0.11) per basic share, in 2021.

Precigen reported a net loss from continuing operations of $25.0 million, or $(0.13) per share, for Q4 2021, compared to a net loss of $39.7 million, or $(0.22) per share, for Q4 2020. Total revenues increased by $4.9 million, or 25%, primarily driven by product and service revenues from Trans Ova and Exemplar.

Precigen announced topline summary of the presentations planned for today’s 2021 R&D Day virtual event, showcasing clinical progress for Precigen’s UltraCAR-T platform and the AdenoVerse Immunotherapy platform. Initial data for PRGN-3005 and PRGN-3006 continue to demonstrate favorable safety profiles, dose-dependent expansion, and durable persistence.

Precigen reported an increase in total revenues by $3.2 million, driven by product and service revenues from Trans Ova and Exemplar. The company experienced an increase in research and development expenses, and a net loss from continuing operations of $20.1 million.

Precigen reported a net loss of $21.8 million, with a decrease in total revenues by $5.3 million compared to the prior year. The company highlighted progress in its clinical programs and the initiation of a Phase 1 study for PRGN-2012.

Precigen reported Q4 2020 revenues of $19.3 million compared to $17.0 million in Q4 2019. The net loss from continuing operations was $39.7 million, or $(0.22) per basic share, compared to a net loss of $64.2 million, or $(0.41) per basic share in Q4 2019. Cash, cash equivalents, and short-term investments totaled $100.1 million as of December 31, 2020.

Precigen reported a revenue increase of 29% to $23.6 million and a reduced net loss from continuing operations of $29.5 million, compared to $49.1 million in the third quarter of 2019. The company highlighted progress in its clinical pipeline, including the dosing of the first patient in the PRGN-2009 Phase I/II trial and advancements in the UltraPorator system.

Precigen reported a second-quarter revenue of $30.4 million and a net loss of $43.4 million, or $(0.26) per basic share. The company highlighted progress in clinical trials and the development of its UltraPorator manufacturing device.

Precigen reported total revenues of $29.8 million and a net loss from continuing operations attributable to Precigen of $29.9 million, or $(0.19) per basic share. Cash, cash equivalents, and short-term investments totaled $149.2 million at March 31, 2020.

Precigen reported Q4 2019 financial results, featuring revenues of $17.0 million from continuing operations and a net loss of $169.2 million, which includes $95.7 million from discontinued operations and $33.8 million in non-cash charges. The company highlighted strategic transactions aimed at focusing on healthcare and completed asset sales and stock offerings to improve its financial position.